____simple_html_dom__voku__html_wrapper____> rrently under development for several neurodegenerative diseases, including ALS, Parkinson’s disease (PD), and multiple sclerosis (MS).

Results of the RESCUE-ALS trial show that patients who took 30 milligrams of CNM-Au8 daily over a prolonged period of time had a significant reduction in disease progression. patients who took 30 milligrams of CNM-Au8 daily over an extended period of time had a 70% reduction in all-cause mortality risk compared to PRO-ACT-prone subjects, and a 51% reduction in all-cause mortality risk compared to MiNDAUS-prone subjects. Clean describes the data from these trials as demonstrating two mechanisms by which the drug supports cranial nerve metabolism and significantly reduces oxidative cellular stress. cnm-Au8 is expected to move forward this year! From Neurology Live

In RESCUE-ALS, long-term treatment with 30 mg of CNM-Au8 revealed a 70% decreased risk of all-cause mortality in comparison with PRO-ACT propensity matched controls (HR, 0.311; 95% CI, 0.142-0.682; covariate adjusted, P = .0035). It also had a 51% decreased risk of all-cause mortality compared with MiNDAUS propensity matched controls (HR, 0.487; 95% CI, 0.287-0.824; covariate adjusted, P = .0074).

The link below will take you to the article by Merisa Wexler. The article includes an explanation of the drug approval process, including the difference between expedited and formal approval, and how the FDA became more positive about expedited approval after positive data were submitted by Clene at a meeting between the FDA and Clene last November.